scholarly journals Autologous 111 Indium‐oxinate‐labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor‐agonists

2019 ◽  
Author(s):  
Matthieu Mahevas ◽  
Sandrine Van Eeckhoudt ◽  
Guillaume Moulis ◽  
Nicolas Limal ◽  
Laetitia Languille ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor

Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era

2020 ◽  
Vol 20 ◽  
Author(s):  
Giuseppe Lassandro ◽  
Valentina Palladino ◽  
Giovanni Carlo Del Vecchioa ◽  
Viviana Valeria Palmieri ◽  
Paola Carmela Corallo ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Treatment Options ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor ◽  
Related Quality ◽  
Health Related

Background and Objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, have been shown to be safety and effective for the treatment of pediatric ITP. The aim of our research is defining the role of thrombopoietin receptor agonists in the management of pediatric ITP. Method: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in clinical routine, highlighting their key role in management of the disease. Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with minor side effects. Conclusion: Although TPO-RAs long term efficacy and safety still require further investigations, their use is gradually expanding in clinical practice of children with ITP.

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms

2012 ◽  
Vol 161 (1) ◽  
pp. 142-144 ◽  
Author(s):  
Nicola Polverelli ◽  
Francesca Palandri ◽  
Ilaria Iacobucci ◽  
Lucia Catani ◽  
Giovanni Martinelli ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Cross Resistance ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor

Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nikola Pantic ◽  
Nada Suvajdzic-Vukovic ◽  
Marijana Virijevic ◽  
Zlatko Pravdic ◽  
Nikica Sabljic ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor ◽  
Chronic Immune Thrombocytopenia

scholarly journals Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients

Blood Reviews ◽  
2020 ◽  
pp. 100774
Author(s):  
Wobke E.M. van Dijk ◽  
Odila N. Brandwijk ◽  
Katja M.J. Heitink-Polle ◽  
Roger E.G. Schutgens ◽  
Karin P.M. van Galen ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor

Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists

Platelets ◽  
2019 ◽  
Vol 31 (3) ◽  
pp. 322-328 ◽  
Author(s):  
Lamya Garabet ◽  
Waleed Ghanima ◽  
Marit Hellum ◽  
Per Morten Sandset ◽  
James B. Bussel ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Thrombin Generation ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor
Sign in / Sign up

Export Citation Format

Share Document